A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.
2014 ◽
Vol 32
(15_suppl)
◽
pp. 8051-8051
◽
Keyword(s):
Phase 2
◽